Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R)

Clinical Research in Cardiology Supplements

Volumn 7, Issue SUPPL.1, 2012, Pages 2-6

  Schaefer, Juergen R ^a   Kurt, Bilgen ^a   Sattler, Alexander ^a   Klaus, Günter ^a   Soufi, Muhidien ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Familial hypercholesterolemia; LDL apheresis; Low density lipoprotein receptor (LDLR); Statin treatment

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN; AZETIDINE DERIVATIVE; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DENATURING GRADIENT GEL ELECTROPHORESIS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENE SEQUENCE; HEART INFARCTION; HUMAN; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DRUG COMBINATION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; METHODOLOGY; MUTATION; PATHOPHYSIOLOGY; PHARMACOGENETICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; DRUG COMBINATIONS; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MUTATION; PHARMACOGENETICS; RECEPTORS, LDL; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84872190580     PISSN: 18610706     EISSN: 18610714     Source Type: Journal    
DOI: 10.1007/s11789-012-0041-y     Document Type: Article

References (30)

1. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47.
2. Cummings RD, Kornfeld S, Schneider WJ, Hobgood KK, Tolleshaug H, Brown MS, Goldstein JL (1983) Biosynthesis of N- and O-linked oligosaccharides of the low density lipoprotein receptor. J Biol Chem 258: 15261-15273.
3. Davis CG, van Driel IR, Russell DW, Brown MS, Goldstein JL (1987) The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. J Biol Chem 262: 4075-4082.
4. Hobbs HH, Russell DW, Brown MS, Goldstein JL (1990) The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24: 133-170.
5. Austin MA, Hutter CM, Zimmern RL, Humphries SE (2004) Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 160: 421-429.
6. Goldstein JL, Brown MS (1989) Familial Hypercholesterolemiahypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds) The metabolic basis of inherited disease. McGraw-Hill, New York pp 1215-1250.
7. Rader DJ, Cohen J, Hobbs HH (2003) Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111: 1795-1803.
8. Sudhof TC, Goldstein JL, Brown MS, Russell DW (1985) The LDL receptor gene: a mosaic of exons shared with different proteins. Science 228: 815-822.
9. Villeger L, Abifadel M, Allard D, Rabes JP, Thiart R, Kotze MJ et al (2002) The UMD-LDLR database: additions to the software and 490 new entries to the database. Hum Mutat 20: 81-87.
10. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE (2008) Update and analysis of the university college london low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 72: 485-498.
11. Varret M, Abifadel M, Rabès JP, Boileau C (2008) Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet 73(1): 1-13.
12. Hobbs HH, Brown MS, Goldstein JL (1992) Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1: 445-466.
13. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
14. Hackler R, Schaefer JR, Motzny S, Brand S, Kleine TO, Kaffarnik H, Steinmetz A (1994) Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using PhastSystem and immunofixation. J Lipid Res 35: 153-158.
15. Nissen H, Guldberg P, Hansen AB, Petersen NE, Horder M (1996) Clinically applicable mutation screening in familial hypercholesterolemia. Hum Mutat 8: 168-177.
16. Soufi M, Sattler AM, Maerz W, Starke A, Herzum M, Maisch B, Schaefer JR (2004) A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis 174: 11-16.
17. Zschocke J, Schaefer JR (2003) Homozygous familial hypercholesterolaemia in identical twins. Lancet 361(9369): 1641.
18. Soufi M, Zschocke J, Quak E, Hofmann G, Maisch B, Schaefer JR (1999) First description of homozygous familial hypercholesterolemia (FH) in twins. Atherosclerosis Suppl. 2(147): 34.
19. Sozen MM, Whittall R, Oner C, Tokatli A, Kalkanoglu HS, Dursun A et al (2005) The molecular basis of familial hypercholesterolaemia in Turkish patients. Atherosclerosis 180: 63-71.
20. Soufi M, Kurt B, Schweer H, Sattler AM, Klaus G, Zschocke J, Schaefer JR (2009) Genetics and kinetics of familial hypercholesterolemia, with the special focus on FH-(Marburg) p. W556R. Atheroscler Suppl 10(5): 5-11.
21. Schmidt HH, Tietge UJ, Buettner J, Barg-Hock H, Offner G, Schweitzer S et al (2008) Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p. W577R LDL-receptor gene mutation. Clin Transplant 22: 180-184.
22. Abramson BL, Benlian P, Hanson ME, Lin J, Shah A, Tershakovec AM (2011) Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22, 231 hyperlipidemic patients. Lipids Health Dis 10: 146.
23. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB (2004) Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79(5): 620-629.
24. Heath KE, Gudnason V, Humphries SE, Seed M (1999) The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 143(1): 41-54.
25. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M (2005) Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics 15(4): 219-225.
26. Graham CA, McClean E, Ward AJ, Beattie ED, Martin S, O'Kane M et al (1999) Mutation screening and genotype: phenotype correlation in familial hypercholesterolaemia. Atherosclerosis 147: 309-316.
27. Vergopoulos A, Knoblauch H, Schuster H (2002) DNA testing for familial hypercholesterolemia: improving disease recognition and patient care. Am J Pharmacogenomics 2(4): 253-262.
28. Guardamagna O, Restagno G, Rolfo E, Pederiva C, Martini S, Abello F et al (2009) The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 155: 199-204.
29. Ned Renée M, Sijbrands Eric JG (2011) Cascade screening for familial hypercholesterolemia (FH) (Internet). Version 11. PLoS currents: evidence on genomic tests. 2011: PMC3102597.
30. Setia N, Verma IC, Khan B, Arora A (2012) Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population. Cardiol Res Pract 2012: 658526. (Epub 27 Oct 2011).